Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
PBYI's Cash to Debt is ranked higher than
74% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. PBYI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PBYI' s 10-Year Cash to Debt Range
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6484
N/A
No Debt
Interest Coverage No Debt
PBYI's Interest Coverage is ranked lower than
54% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PBYI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PBYI' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 63.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -99.76
PBYI's ROE (%) is ranked lower than
80% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. PBYI: -99.76 )
Ranked among companies with meaningful ROE (%) only.
PBYI' s 10-Year ROE (%) Range
Min: -141.23  Med: -66.24 Max: -37.64
Current: -99.76
-141.23
-37.64
ROA (%) -86.03
PBYI's ROA (%) is ranked lower than
81% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. PBYI: -86.03 )
Ranked among companies with meaningful ROA (%) only.
PBYI' s 10-Year ROA (%) Range
Min: -1700  Med: -89.05 Max: -36.94
Current: -86.03
-1700
-36.94
ROC (Joel Greenblatt) (%) -9140.06
PBYI's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. PBYI: -9140.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PBYI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7408.23  Med: -5178.74 Max: -2978.59
Current: -9140.06
-7408.23
-2978.59
EBITDA Growth (3Y)(%) 53.30
PBYI's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. PBYI: 53.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PBYI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 26.65 Max: 598.6
Current: 53.3
0
598.6
EPS Growth (3Y)(%) 53.00
PBYI's EPS Growth (3Y)(%) is ranked higher than
93% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. PBYI: 53.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PBYI' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: 326.15 Max: 883
Current: 53
0
883
» PBYI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

PBYI Guru Trades in Q3 2014

Jim Simons 30,200 sh (New)
RS Investment Management 92,188 sh (New)
Steven Cohen Sold Out
» More
Q4 2014

PBYI Guru Trades in Q4 2014

Jim Simons Sold Out
RS Investment Management Sold Out
» More
Q1 2015

PBYI Guru Trades in Q1 2015

Steven Cohen 9,100 sh (New)
» More
Q2 2015

PBYI Guru Trades in Q2 2015

Jeremy Grantham 1,426,738 sh (New)
Steven Cohen 68,600 sh (+653.85%)
» More
» Details

Insider Trades

Latest Guru Trades with PBYI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.57
PBYI's P/B is ranked lower than
82% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. PBYI: 10.57 )
Ranked among companies with meaningful P/B only.
PBYI' s 10-Year P/B Range
Min: 0  Med: 0.00 Max: 62.4
Current: 10.57
0
62.4
Current Ratio 11.03
PBYI's Current Ratio is ranked higher than
78% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. PBYI: 11.03 )
Ranked among companies with meaningful Current Ratio only.
PBYI' s 10-Year Current Ratio Range
Min: 0.67  Med: 5.60 Max: 91.42
Current: 11.03
0.67
91.42
Quick Ratio 11.03
PBYI's Quick Ratio is ranked higher than
78% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. PBYI: 11.03 )
Ranked among companies with meaningful Quick Ratio only.
PBYI' s 10-Year Quick Ratio Range
Min: 0.67  Med: 5.60 Max: 91.42
Current: 11.03
0.67
91.42

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.40
PBYI's Price/Net Cash is ranked lower than
65% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. PBYI: 11.40 )
Ranked among companies with meaningful Price/Net Cash only.
PBYI' s 10-Year Price/Net Cash Range
Min: 4.69  Med: 17.96 Max: 60.47
Current: 11.4
4.69
60.47
Price/Net Current Asset Value 11.16
PBYI's Price/Net Current Asset Value is ranked lower than
68% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. PBYI: 11.16 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PBYI' s 10-Year Price/Net Current Asset Value Range
Min: 4.26  Med: 16.50 Max: 55.83
Current: 11.16
4.26
55.83
Price/Tangible Book 10.57
PBYI's Price/Tangible Book is ranked lower than
76% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. PBYI: 10.57 )
Ranked among companies with meaningful Price/Tangible Book only.
PBYI' s 10-Year Price/Tangible Book Range
Min: 4.18  Med: 15.78 Max: 50.76
Current: 10.57
4.18
50.76
Earnings Yield (Greenblatt) (%) -7.62
PBYI's Earnings Yield (Greenblatt) (%) is ranked lower than
53% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. PBYI: -7.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PBYI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -8.69  Med: 0.00 Max: 0
Current: -7.62
-8.69
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 178
EPS($) -6.46 -6.17 -3.91
EPS without NRI($) -6.46 -6.17 -3.91

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0PB.Germany,
Puma Biotechnology Inc was incorporated in Delaware on April 27, 2007. The Company is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care It is engaged in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The Company currently licenses the rights to three drug candidates: PB272 (neratinib (oral)), which are being developed for the treatment of breast cancer patients, non-small cell lung cancer and patients with HER2 mutation-positive solid tumors; PB272 (neratinib (intravenous)), which are being developed for the treatment of cancer patients; and PB357, which it believes can serve as a backup compound to PB272, and which are being evaluated for further development. The Company focused on developing neratinib for the treatment of patients with human epidermal growth factor receptor type 2, or HER2-positive, breast cancer, HER2 mutated non-small cell lung cancer, HER2-negative breast cancer that has a HER2 mutation and other solid tumors that have an activating mutation in HER2. Therapeutic strategies, such as the use of Herceptin (trastuzumab), Perjeta (pertuzumab), and Kadcyla (T-DM1), produced by Genentech, and Tykerb (lapatinib), produced by GlaxoSmithKline, given either alone or in combination with chemotherapy, have been developed to improve the treatment of this cancer by binding to the HER2 protein. The Company licenses the exclusive rights to its current drug candidates from Pfizer Inc., or Pfizer, which had previously been responsible for the clinical trials regarding neratinib. The Company's competitors include Genentech, GlaxoSmithKline, Roche, Boehringer Ingelheim, Takeda, Array Biopharma and Ambit Biosciences.
» More Articles for PBYI

Headlines

Articles On GuruFocus.com
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 

More From Other Websites
Jim Cramer's Top Takeaways: Puma Biotechnology and H&R Block Sep 03 2015
Jim Cramer's 'Mad Money' Recap: A Rally or Calm Before the Storm? Sep 02 2015
Cramer Remix: What sent the market higher? Sellers Sep 02 2015
Cramer: Are high-reward biotech bargains worth it? Sep 02 2015
Cramer: Are high-reward biotech bargains worth it? Sep 02 2015
Cramer: What pushed this market higher? The sellers Sep 02 2015
Puma Biotech Is Wounded, But May Have Claws: JP Morgan Aug 27 2015
Coverage initiated on Puma Biotech. by JP Morgan Aug 27 2015
PUMA BIOTECHNOLOGY, INC. Financials Aug 20 2015
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers Aug 14 2015
Mid-Day Market Update: Wednesday's Movers, China Intervenes With Yuan And Kraft Heinz Job Cut Aug 12 2015
Puma Biotechnology's (PBYI) Q2 Loss Wider than Expected Aug 12 2015
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of... Aug 11 2015
Puma Biotech reports 2Q loss Aug 10 2015
Puma Biotech reports 2Q loss Aug 10 2015
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 10 2015
Puma Biotechnology Reports Second Quarter 2015 Financial Results Aug 10 2015
PUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report Aug 10 2015
Will Puma Biotechnology (PBYI) Surprise in Q2 Earnings? - Analyst Blog Aug 06 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of... Jul 31 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK